FDA Commissioner Marty Makary wrote in a two-page memo on Wednesday last week that the agency “does not intend to enforce” certain sections of the Federal Food, Drug, and Cosmetic Act..."
What this means is that FDA won’t stand in the way of the proposed Medicare plans to cover up to $500 for CBD products for Medicare recipients. While the memo stops short of explicitly endorsing CBD as a covered medical benefit, the language signals a notable shift in how federal agencies may approach cannabis-derived products—particularly those widely used for pain, anxiety, and sleep disorders among older adults.
For years, CBD has existed in a regulatory gray area. Despite its widespread availability in oils, capsules, and topical products, the FDA has consistently maintained that CBD cannot be marketed as a dietary supplement or added to food without formal approval. This stance has limited its integration into traditional healthcare systems, including Medicare. However, the agency’s decision not to enforce certain provisions suggests a significantly more flexible, perhaps pragmatic, approach.
If Medicare were to finalize up to $500 in annual CBD coverage, the implications could be significant. Millions of seniors, including Imbue customers, might receive some Medicare coverage on products they already use. Advocates argue this could reduce reliance on prescription medications, particularly opioids, which carry higher risks of dependency and side effects. While the details have yet to be fully established, a healthcare providers recommendation or prescription would be required.
While Imbue has always been focused on quality control, the CBD market has been criticized for inconsistent labeling, variable potency, and contamination risks. If taxpayer dollars are used to subsidize these products, there will likely be increased pressure to establish clear standards and approved product lists, something we here at Imbue fully support.
Additionally, the scientific community remains divided. While current research and anecdotal evidence support potential benefits of CBD, large-scale clinical trials are still limited. Critics warn that expanding coverage without robust evidence could set a precedent for funding treatments that lack sufficient validation.
There’s also the political dimension. Cannabis policy in the United States continues to evolve at both state and federal levels, and CBD—while federally legal under certain conditions—remains tied to broader debates about marijuana legalization. This development could be seen as another step toward normalization, especially within federal programs.
For now, the memo does not guarantee immediate changes. Medicare policies involve multiple layers of approval, and any new benefit would require clear guidelines on eligibility, product types, and reimbursement processes. However, the FDA’s stance may remove a key barrier that previously made such proposals difficult to consider.
In the coming months, we’ll be watching closely. Whether this leads to full-scale coverage or simply opens the door to further discussion, one thing is clear: the conversation around CBD is no longer on the fringes. It’s entering the mainstream of American healthcare policy.
